United Therapeutics Co. (NASDAQ:UTHR) Stock Position Boosted by Vontobel Holding Ltd.

Vontobel Holding Ltd. grew its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 90.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,664 shares of the biotechnology company’s stock after buying an additional 790 shares during the quarter. Vontobel Holding Ltd.’s holdings in United Therapeutics were worth $596,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the stock. Meiji Yasuda Asset Management Co Ltd. raised its holdings in United Therapeutics by 1.6% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock worth $652,000 after purchasing an additional 33 shares in the last quarter. Toronto Dominion Bank increased its position in shares of United Therapeutics by 0.8% during the 2nd quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock valued at $1,441,000 after purchasing an additional 37 shares during the period. ClariVest Asset Management LLC raised its stake in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after buying an additional 42 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its stake in United Therapeutics by 14.0% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 42 shares in the last quarter. Finally, Access Investment Management LLC boosted its stake in United Therapeutics by 0.8% during the second quarter. Access Investment Management LLC now owns 7,265 shares of the biotechnology company’s stock valued at $2,314,000 after buying an additional 55 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on UTHR shares. LADENBURG THALM/SH SH cut United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. Bank of America reduced their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a report on Thursday, August 1st. TD Cowen boosted their price objective on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday. Wells Fargo & Company upped their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. Finally, StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $361.33.

Insider Activity at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $338.61, for a total transaction of $1,218,996.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $44,019.30. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $338.61, for a total transaction of $1,218,996.00. Following the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $44,019.30. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 269 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $348.41, for a total value of $93,722.29. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $45,293.30. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 102,230 shares of company stock valued at $34,817,406. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Trading Up 0.6 %

NASDAQ UTHR opened at $370.60 on Tuesday. The company has a market capitalization of $16.49 billion, a PE ratio of 17.03, a price-to-earnings-growth ratio of 1.34 and a beta of 0.57. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $377.03. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. The firm’s fifty day simple moving average is $350.66 and its 200-day simple moving average is $309.00.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The firm had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same period last year, the business earned $5.24 earnings per share. As a group, sell-side analysts anticipate that United Therapeutics Co. will post 24.72 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.